Literature DB >> 9384654

An asymptotic analysis of the logrank test.

R L Strawderman1.   

Abstract

Asymptotic expansions for the null distribution of the logrank statistic and its distribution under local proportional hazards alternatives are developed in the case of iid observations. The results, which are derived from the work of Gu (1992) and Taniguchi (1992), are easy to interpret, and provide some theoretical justification for many behavioral characteristics of the logrank test that have been previously observed in simulation studies. We focus primarily upon (i) the inadequacy of the usual normal approximation under treatment group imbalance; and, (ii) the effects of treatment group imbalance on power and sample size calculations. A simple transformation of the logrank statistic is also derived based on results in Konishi (1991) and is found to substantially improve the standard normal approximation to its distribution under the null hypothesis of no survival difference when there is treatment group imbalance.

Mesh:

Year:  1997        PMID: 9384654     DOI: 10.1023/a:1009648914586

Source DB:  PubMed          Journal:  Lifetime Data Anal        ISSN: 1380-7870            Impact factor:   1.588


  7 in total

1.  Comparing sample size formulae for trials with unbalanced allocation using the logrank test.

Authors:  F Y Hsieh
Journal:  Stat Med       Date:  1992-06-15       Impact factor: 2.373

2.  A comparison of sample size methods for the logrank statistic.

Authors:  E Lakatos; K K Lan
Journal:  Stat Med       Date:  1992-01-30       Impact factor: 2.373

3.  A simple method of sample size calculation for unequal-sample-size designs that use the logrank or t-test.

Authors:  F Y Hsieh
Journal:  Stat Med       Date:  1987 Jul-Aug       Impact factor: 2.373

4.  Use of unequal allocation in survival trials.

Authors:  R Sposto; M D Krailo
Journal:  Stat Med       Date:  1987-03       Impact factor: 2.373

5.  Efficiency of balanced treatment allocation for survival analysis.

Authors:  L A Kalish; D P Harrington
Journal:  Biometrics       Date:  1988-09       Impact factor: 2.571

6.  A qualitative discrepancy between censored data rank tests.

Authors:  R L Prentice; P Marek
Journal:  Biometrics       Date:  1979-12       Impact factor: 2.571

7.  Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples.

Authors:  R Peto; M C Pike; P Armitage; N E Breslow; D R Cox; S V Howard; N Mantel; K McPherson; J Peto; P G Smith
Journal:  Br J Cancer       Date:  1977-01       Impact factor: 7.640

  7 in total
  4 in total

1.  A genome-wide association study for venous thromboembolism: the extended cohorts for heart and aging research in genomic epidemiology (CHARGE) consortium.

Authors:  Weihong Tang; Martina Teichert; Daniel I Chasman; John A Heit; Pierre-Emmanuel Morange; Guo Li; Bruno H Ch Stricker; Paul M Ridker; Aaron R Folsom; Nicholas L Smith; Nathan Pankratz; Frank W Leebeek; Guillaume Paré; Mariza de Andrade; Christophe Tzourio; Bruce M Psaty; Saonli Basu; Rikje Ruiter; Lynda Rose; Sebastian M Armasu; Thomas Lumley; Susan R Heckbert; André G Uitterlinden; Mark Lathrop; Kenneth M Rice; Mary Cushman; Albert Hofman; Jean-Charles Lambert; Nicole L Glazer; James S Pankow; Jacqueline C Witteman; Philippe Amouyel; Joshua C Bis; Edwin G Bovill; Xiaoxiao Kong; Russell P Tracy; Eric Boerwinkle; Jerome I Rotter; David-Alexandre Trégouët; Daan W Loth
Journal:  Genet Epidemiol       Date:  2013-05-05       Impact factor: 2.135

2.  A logrank test-based method for sizing clinical trials with two co-primary time-to-event endpoints.

Authors:  Tomoyuki Sugimoto; Takashi Sozu; Toshimitsu Hamasaki; Scott R Evans
Journal:  Biostatistics       Date:  2013-01-10       Impact factor: 5.899

3.  Sizing clinical trials when comparing bivariate time-to-event outcomes.

Authors:  Tomoyuki Sugimoto; Toshimitsu Hamasaki; Scott R Evans; Takashi Sozu
Journal:  Stat Med       Date:  2017-01-24       Impact factor: 2.373

4.  Increasing the power of randomized trials comparing different treatment durations.

Authors:  Yongdong Ouyang; Hong Qian; Lakshmi N Yatham; Hubert Wong
Journal:  Contemp Clin Trials Commun       Date:  2020-06-10
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.